Vol. 11 No. 1 (2017): January-December 2017

Original Research Article

Short communication

  • Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill

    Jagannadha Avasarala
    DOI: https://doi.org/10.33393/dti.2017.1367